|
|
Actions taken by firms to remove problem products
from the market. Recalls may be conducted on a firm's own initiative,
by FDA request, or by FDA order under statutory authority.
Sent from FDA to regulated companies about regulatory issues.
A weekly report of FDA regulatory activities.
Identify problems with commodities and shippers and provide
guidance to FDA field investigators about import coverage.
Notices about imported products that FDA has detained because
appear to be out of compliance with the Federal Food, Drug,
and Cosmetic Act.
"Cyberletters" and other information about actions
involving Websites whose offers to sell prescription drugs
online may be illegal.
|
|
|
|
Individuals or firms barred from participating
in the drug industry because they have been convicted of crimes
related to FDA's regulation of drugs.
Clinical investigators who have at one time been disqualified,
restricted, or have agreed to certain restrictions on their
conduct in future studies. If an investigator has been reinstated
or restrictions have expired, it is so noted.
Researchers who have had administrative actions imposed against
them by the Office of Research Integrity (ORI).
Letters issued by FDA when it believes that a clinical investigator
repeatedly or deliberately violated FDA's regulations governing
the proper conduct of clinical studies involving investigational
products or submitted false information to the sponsor.
|
|
|
|
|
|